Brief: Bubs Australia Says Bubs Infant Formula Q1 Gross Revenue Of A$17.5M, Up 41% On Pcp

Bubs Australia

24/10/2023 02:41

Oct 24 (Reuters) - Bubs Australia  BUB.AX :
    * BUBS INFANT FORMULA Q1 GROSS REVENUE OF A$17.5M, UP 41% ON
PCP
    * US FDA PERMANENT ACCESS PROCESS REMAINS ON TRACK WITH
CLINICAL
TRIAL UNDERWAY
    * Q1 GROUP GROSS REVENUE OF A$24.3MLN, UP 3.4% PRIOR
CORRESPONDING
PERIOD
    * MAKING SIGNIFICANT INVESTMENT AND INCURRING SIGNIFICANT
COSTS
ASSOCIATED WITH FDA APPROVAL PROCESS OF A$2.9M IN Q1 FY24
    * FDA APPROVAL COSTS WHILST ONE-OFF AND NON-RECURRING IN
NATURE,
WILL CONTINUE THROUGHOUT FY24 ALBEIT FRONT END LOADED

Source text for Eikon:  ID:nASX4tV94y 
Further company coverage:  BUB.AX 

 ((Reuters.Briefs@thomsonreuters.com;))